Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Intangibles (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Intangibles for 5 consecutive years, with $15.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles fell 6.06% year-over-year to $15.5 million, compared with a TTM value of $15.5 million through Sep 2025, down 6.06%, and an annual FY2024 reading of $16.2 million, down 5.8% over the prior year.
  • Intangibles was $15.5 million for Q3 2025 at Kiniksa Pharmaceuticals International, down from $16.2 million in the prior quarter.
  • Across five years, Intangibles topped out at $20.0 million in Q1 2021 and bottomed at $15.5 million in Q3 2025.
  • Average Intangibles over 5 years is $17.9 million, with a median of $17.5 million recorded in 2023.
  • Peak annual rise in Intangibles hit 5.0% in 2022, while the deepest fall reached 8.75% in 2022.
  • Year by year, Intangibles stood at $20.0 million in 2021, then dropped by 8.75% to $18.2 million in 2022, then dropped by 5.48% to $17.2 million in 2023, then decreased by 5.8% to $16.2 million in 2024, then fell by 4.62% to $15.5 million in 2025.
  • Business Quant data shows Intangibles for KNSA at $15.5 million in Q3 2025, $16.2 million in Q4 2024, and $16.5 million in Q3 2024.